Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer

Suresh S. Ramalingam, Taofeek K. Owonikoko, Madhusmita Behera, Janakiraman Subramanian, Nabil F. Saba, Scott A. Kono, Anthony A. Gal, Gabriel Sica, R. Donald Harvey, Zhengjia Chen, Carmen M. Klass, Dong M. Shin, Haian Fu, Shi Yong R. Sun, Ramaswamy Govindan, Fadlo R. Khuri

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science